´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19±³À°ÀÏÀÚ : 2020-11-19
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2020 KALC International Conference ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 08:00~08:25 Extracellular Vesicle Liquid Biopsy ÇãÀ翵(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 08:25~08:50 Multiplex Molecular and Histopathology in Lung Cancer ±èÅÂÁ¤(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 08:50~09:15 Liquid Biopsy Approaches for EGFR Mutant NSCLC Patients Therese Becker(Ingham Institute for Applied Medical Research)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 09:15~09:40 High-plex Methods for Biomarker Discovery David Rimm(Yale University School of Medicine)
ÈÞ½Ä 11¿ù 19ÀÏ 09:40~09:50 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 09:50~10:40 ¡°Turn Your Face To Hope For The Patients¡±: Pembrolizumab in the 1st-line metastatic squamous NSCLC ÀÓ¼±¹Î(ºÐ´ç¼¿ïÀÇ´ë)
ÈÞ½Ä 11¿ù 19ÀÏ 10:40~10:50 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 10:50~11:15 Incorporation of Immuno-oncology in SCLC À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 11:15~11:40 Novel Therapeutic Approaches in SCLC ÀÌ°æ¿ø(°æ»óÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 11:40~12:05 Recent Update in Thymic Malignancy Treatment ±è¼¼Çö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 12:05~12:30 Multidisciplinary Approach for Malignant Mesothelioma ¹ÚÁöÇö(°Ç±¹ÀÇ´ë)
ÈÞ½Ä 11¿ù 19ÀÏ 12:30~12:40 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 12:40~13:05 Salvage Operation after Definitive CCRTx Jessica Donington(University of Chicago)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:05~13:30 Salvage Surgery for Advanced Non-small Cell Lung Cancer after Targeted Therapy Tomoyuki Hishida(Keio University School of Medicine)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:30~13:55 Experience of Pulmonary Resection after Immunotherapy ¹Ú½Â¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:55~14:20 Pulmonary Resection after Neoadjuvant Therapy ±èÈ«°ü(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 11¿ù 19ÀÏ 14:20~14:30 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 14:30~14:55 Review of SABR versus Surgery Trials ¿ìÈ«±Õ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 14:55~15:20 Surgery as a Primary Treatment for Early Lung Masatsugu Hamaji(Kyoto University)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 15:20~15:45 SABR as a Primary Treatment for Early Lung Cancer Á¶ÀçÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 15:45~16:10 Combination of SABR and Immunotherapy for Lung Cancer Joe Y. Chang(The University of Texas MD Anderson Cancer Center)
ÈÞ½Ä 11¿ù 19ÀÏ 16:10~16:20 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 16:20~17:00 Clonal Heterogeneity and Lung Cancer Evolution: Lung TRACERx Charles Swanton(Cancer Evolution and Genome Instability Laboratory)
ÈÞ½Ä 11¿ù 19ÀÏ 17:00~17:10 Break ()
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 17:10~17:50 10-Year and Beyond Results in NELSON Lung Cancer Screening Study Harry J. de Koning(Erasmus University Medical Center)